Head & Neck Radiotherapy & Osteoradionecrosis Risk

Therapeutic head-and-neck radiotherapy permanently alters the bone that an implant must integrate into. The classic triad described by Marx — hypovascularity, hypocellularity, and hypoxia — leaves irradiated bone with diminished capacity to heal, to mount an angiogenic response, and to remodel against a titanium surface. Against this background, every osteotomy in irradiated bone carries a risk found almost nowhere else in implant dentistry: osteoradionecrosis (ORN), the progressive death of irradiated bone that fails to heal over exposed, devitalized cortex. The clinician's task is therefore not the familiar one of optimizing osseointegration, but the harder one of deciding whether to enter the bone at all.¹²

Three variables dominate that decision and recur throughout this section. The first is radiation dose to the implant site — not the prescribed tumour dose, but the dose actually delivered to the proposed bone, which must be read from the radiation-oncology dose plan. Risk rises appreciably as site dose climbs through roughly 50–60 Gy, and becomes markedly elevated above 60 Gy; yet — importantly — the dose–risk relationship is contested, and at least one systematic review found no clean threshold for ORN.³⁴ The second is anatomic site: the mandible, with its denser cortex and comparatively end-arterial supply, carries substantially higher ORN risk than the better-vascularized maxilla, and the posterior mandible is the most vulnerable region of all.⁵ The third is timing relative to therapy — whether the implant is placed before radiotherapy, soon after, or following a recovery interval. These three converge on a single triage logic: proceed with caution, defer and plan, or avoid and refer.

One further controversy must be flagged at the outset. For decades, perioperative hyperbaric oxygen (HBO) was offered to reduce ORN risk around surgery in irradiated bone. That practice is no longer supported by the best evidence: randomized trials — notably HOPON and DAHANCA-21 — failed to demonstrate a clear benefit, and contemporary guidance no longer endorses routine prophylactic HBO.⁶⁷ Throughout this section the evidence is largely observational, thresholds are debated, and the appropriate posture is conservatism plus multidisciplinary co-management.

ORN risk is a function of how much radiation the bone received, which bone it was, and when surgery is contemplated relative to therapy. No single figure is universally agreed; the values below are convergence points across reviews rather than hard cut-offs, and should be treated as decision aids, not licences.

Dose to the site

Radiation dose is the dominant variable. Reported dental-implant survival is meaningfully higher below 50 Gy than above it — in pooled data, on the order of ~84% below 50 Gy versus ~71% above 50 Gy — and ORN incidence after standard fractionation to 60–72 Gy has historically been reported in the 5–15% range, falling toward 1–6% with modern moderately accelerated or hyperfractionated regimens.³⁹ The biological mechanism is loss of bone vascularity and cellularity: above roughly 50–60 Gy, the bone's reparative reserve is progressively exhausted. Dosimetric studies of the mandible find the volume of bone receiving ≥50 Gy (V50) to be among the strongest predictors of ORN.⁸ And yet the relationship is genuinely debated: a rigorous systematic review concluded that the literature does not support the often-proclaimed dose-dependent increase or any single threshold value — a caveat that should temper any reflexive use of "50 Gy" or "60 Gy" as a bright line.⁴

Anatomic site — mandible > maxilla

For any given dose, the mandible is the higher-risk bone. Its dense cortex and relatively end-arterial blood supply make it slower to revascularize after injury, and the posterior mandible is the most vulnerable region. The maxilla, by contrast, is better vascularized through a richer collateral supply and carries a substantially lower ORN incidence.⁵ Intensity-modulated radiotherapy (IMRT) has materially reduced mandibular ORN by sparing bone volume, and forward planning with the radiation oncologist can, in some cases, protect a future implant site.⁹

Timing relative to radiotherapy

Implants may be placed before radiotherapy, in which case the surgery itself avoids irradiated bone but may constrain the radiation fields and complicate planning. Placed after radiotherapy, a delayed interval permits partial tissue recovery; many authorities advise waiting at least 6–12 months after radiotherapy for elective placement where feasible. Crucially, the elevated ORN risk does not fully resolve with time: it persists, in attenuated form, for the patient's lifetime, and informed consent must say so.¹²

The synthesis of dose, site, and timing resolves into three broad pathways: proceed with caution, defer and plan, or avoid and refer. The interactive selector below triages a case to one of these by its dominant dose band, adjusted for site and timing. It is a teaching and triage aid only — it does not replace multidisciplinary review, examination, or the actual dose plan.

When a case clears the gates and implantation is pursued, the operative principles are uniform across risk bands and differ only in stringency. Atraumatic surgery — minimal flap elevation, sharp instrumentation, copious irrigation, and avoidance of thermal and compressive trauma — protects what little reparative reserve the irradiated bone retains. Meticulous asepsis reduces the bacterial insult that can tip devitalized bone into frank necrosis. Staged, unhurried loading respects the slower, attenuated osseointegration of irradiated bone, in which the stability hand-off described in Osseointegration: A Cellular Timeline → proceeds against a compromised vascular and cellular background. Above all, close lifelong follow-up is mandatory: any non-healing socket, exposed bone, or persistent pain must be acted on early, because established ORN is far harder to treat than to prevent.²

The hyperbaric oxygen controversy

The role of HBO deserves explicit treatment because it remains widely requested. The historical rationale — that hyperbaric oxygen raises tissue oxygen tension, stimulates angiogenesis, and thereby "prepares" irradiated bone for surgery — is biologically plausible but has not survived randomized testing. The HOPON trial randomized patients requiring dental extractions or mandibular implant placement after radiotherapy > 50 Gy and found ORN at six months in 6.4% of the HBO group versus 5.7% of controls — no significant difference, and a low overall incidence that makes routine prophylactic HBO difficult to justify.⁶ The combined analysis of DAHANCA-21 and a parallel Dutch trial, addressing HBO as an adjunct to surgery for established ORN, likewise failed to demonstrate a statistically significant healing benefit over standard surgical care.⁷ Contemporary multidisciplinary guidance — the ISOO–MASCC–ASCO guideline — accordingly does not endorse routine prophylactic HBO and frames its use as case-by-case at best.² The practical message is to neither offer HBO reflexively nor rely on it as a safety net.